Implementing machine learning in bipolar diagnosis in China.

Journal: Translational psychiatry
PMID:

Abstract

Bipolar disorder (BPD) is often confused with major depression, and current diagnostic questionnaires are subjective and time intensive. The aim of this study was to develop a new Bipolar Diagnosis Checklist in Chinese (BDCC) by using machine learning to shorten the Affective Disorder Evaluation scale (ADE) based on an analysis of registered Chinese multisite cohort data. In order to evaluate the importance of each item of the ADE, a case-control study of 360 bipolar disorder (BPD) patients, 255 major depressive disorder (MDD) patients and 228 healthy (no psychiatric diagnosis) controls (HCs) was conducted, spanning 9 Chinese health facilities participating in the Comprehensive Assessment and Follow-up Descriptive Study on Bipolar Disorder (CAFÉ-BD). The BDCC was formed by selected items from the ADE according to their importance as calculated by a random forest machine learning algorithm. Five classical machine learning algorithms, namely, a random forest algorithm, support vector regression (SVR), the least absolute shrinkage and selection operator (LASSO), linear discriminant analysis (LDA) and logistic regression, were used to retrospectively analyze the aforementioned cohort data to shorten the ADE. Regarding the area under the receiver operating characteristic (ROC) curve (AUC), the BDCC had high AUCs of 0.948, 0.921, and 0.923 for the diagnosis of MDD, BPD, and HC, respectively, despite containing only 15% (17/113) of the items from the ADE. Traditional scales can be shortened using machine learning analysis. By shortening the ADE using a random forest algorithm, we generated the BDCC, which can be more easily applied in clinical practice to effectively enhance both BPD and MDD diagnosis.

Authors

  • Yantao Ma
    Peking University Sixth Hospital, Beijing, China.
  • Jun Ji
    College of Computer Science and Technology, Qingdao University, Qingdao, China.
  • Yun Huang
    Peking University Sixth Hospital, Beijing, China.
  • Huimin Gao
    Peking University Sixth Hospital, Beijing, China.
  • Zhiying Li
    Peking University Sixth Hospital, Beijing, China.
  • Wentian Dong
    Peking University Sixth Hospital, Peking University Institute of Mental Health, Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.
  • Shuzhe Zhou
    Peking University Sixth Hospital, Beijing, China.
  • Yue Zhu
    The National Center for Drug Screening and the CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Weimin Dang
    Peking University Sixth Hospital, Peking University Institute of Mental Health, Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.
  • Tianhang Zhou
    Peking University Sixth Hospital, Beijing, China.
  • Haiqing Yu
    Beijing Wanling Pangu Science and Technology Ltd, Beijing, China.
  • Bin Yu
    Department of Anesthesiology, Peking University First Hospital, Ningxia Women's and Children's Hospital, Yinchuan, China.
  • Yuefeng Long
    Beijing Wanling Pangu Science and Technology Ltd, Beijing, China.
  • Long Liu
    Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Gary Sachs
    Harvard University Massachusetts General Hospital, Boston, MA, USA.
  • Xin Yu
    eSep Inc., Keihanna Open Innovation Center @ Kyoto (KICK), Annex 320, 7-5-1, Seikadai, Seika-cho, Soraku-gun, Kyoto 619-0238, Japan.